Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.

Muñoz R, Hileeto D, Cruz-Muñoz W, Wood GA, Xu P, Man S, Viloria-Petit A, Kerbel RS.

PLoS One. 2019 Sep 19;14(9):e0222580. doi: 10.1371/journal.pone.0222580. eCollection 2019.

2.

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.

Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS.

EMBO Mol Med. 2014 Dec;6(12):1561-76. doi: 10.15252/emmm.201403989.

3.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2015 May 1;21(9):2138-47. doi: 10.1158/1078-0432.CCR-14-0861. Epub 2014 Oct 14.

4.

Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

Cruz-Muñoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, Collins C, Banville M, O'Connor-McCourt MD, Kerbel RS.

Angiogenesis. 2014 Jul;17(3):661-73. doi: 10.1007/s10456-014-9422-9. Epub 2014 Feb 26.

5.

Development and characterization of a clinically relevant mouse model of melanoma brain metastasis.

Morsi A, Gaziel-Sovran A, Cruz-Munoz W, Kerbel RS, Golfinos JG, Hernando E, Wadghiri YZ.

Pigment Cell Melanoma Res. 2013 Sep;26(5):743-5. doi: 10.1111/pcmr.12114. Epub 2013 Jun 4. No abstract available.

6.

Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.

Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS.

Cancer Res. 2012 Oct 1;72(19):4909-19. doi: 10.1158/0008-5472.CAN-12-2194. Epub 2012 Aug 3.

7.

Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS.

Nat Rev Cancer. 2011 Feb;11(2):135-41. doi: 10.1038/nrc3001. Review.

8.

Preclinical approaches to study the biology and treatment of brain metastases.

Cruz-Muñoz W, Kerbel RS.

Semin Cancer Biol. 2011 Apr;21(2):123-30. doi: 10.1016/j.semcancer.2010.12.001. Epub 2010 Dec 13. Review.

9.

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, Kerbel RS.

Mol Cancer Ther. 2010 Apr;9(4):996-1006. doi: 10.1158/1535-7163.MCT-09-0960. Epub 2010 Apr 6.

10.

Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.

Cruz-Munoz W, Man S, Kerbel RS.

Clin Cancer Res. 2009 Aug 1;15(15):4867-74. doi: 10.1158/1078-0432.CCR-08-3275. Epub 2009 Jul 21.

11.

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS.

Cancer Cell. 2009 Mar 3;15(3):232-9. doi: 10.1016/j.ccr.2009.01.021.

12.

The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis.

Cruz-Munoz W, Khokha R.

Crit Rev Clin Lab Sci. 2008;45(3):291-338. doi: 10.1080/10408360801973244 . Review.

PMID:
18568853
13.

Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.

Cruz-Munoz W, Man S, Xu P, Kerbel RS.

Cancer Res. 2008 Jun 15;68(12):4500-5. doi: 10.1158/0008-5472.CAN-08-0041.

14.

Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.

Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, Kouri A, Coke R, Cruz-Munoz W, Ludeman SM, Colvin OM, Kerbel RS.

Mol Cancer Ther. 2007 Aug;6(8):2280-9. Epub 2007 Aug 1.

15.

Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3-/- mice.

Cruz-Munoz W, Sanchez OH, Di Grappa M, English JL, Hill RP, Khokha R.

Oncogene. 2006 Oct 19;25(49):6489-96. Epub 2006 May 15.

PMID:
16702949
16.

TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis.

Cruz-Muñoz W, Kim I, Khokha R.

Oncogene. 2006 Jan 26;25(4):650-5.

PMID:
16186800
17.

ENU induces mutations in the heart of lacZ transgenic mice.

Cruz-Munoz W, Kalair W, Cosentino L, Heddle JA.

Mutat Res. 2000 Aug 21;469(1):23-34.

PMID:
10946239
18.

The cII locus in the MutaMouse system.

Swiger RR, Cosentino L, Shima N, Bielas JH, Cruz-Munoz W, Heddle JA.

Environ Mol Mutagen. 1999;34(2-3):201-7.

PMID:
10529745

Supplemental Content

Loading ...
Support Center